BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 37076694)

  • 1. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
    Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
    Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting miR-126 in Ph+ acute lymphoblastic leukemia.
    Qiao J; Zhao D; Nguyen LXT; Chen F; Liang C; Estrella K; Ghoda LY; Heisterkamp N; Marcucci EC; Kuo YH; Marcucci G; Zhang B
    Leukemia; 2023 Jul; 37(7):1540-1544. PubMed ID: 37296274
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.
    Aureli A; Marziani B; Venditti A; Sconocchia T; Sconocchia G
    Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
    Raetz EA; Rebora P; Conter V; Schrappe M; Devidas M; Escherich G; Imai C; De Moerloose B; Schmiegelow K; Burns MA; Elitzur S; Pieters R; Attarbaschi A; Yeoh A; Pui CH; Stary J; Cario G; Bodmer N; Moorman AV; Buldini B; Vora A; Valsecchi MG
    J Clin Oncol; 2023 Nov; 41(32):5025-5034. PubMed ID: 37487146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic or pre-emptive therapies to prevent relapse after allogeneic hematopoietic stem cell transplantation.
    Kako S
    Int J Hematol; 2023 Aug; 118(2):155-157. PubMed ID: 37418118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poverty and health equity in childhood leukemia.
    Gramatges MM
    Blood; 2023 Jul; 142(3):211-212. PubMed ID: 37471111
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
    Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
    Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.
    Lynggaard LS; Rank CU; Als-Nielsen B; Hoejfeldt SG; Heyman M; Schmiegelow K; Albertsen BK
    Cochrane Database Syst Rev; 2023 May; 5(5):CD014570. PubMed ID: 37260073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.
    Gao Q; Ryan SL; Iacobucci I; Ghate PS; Cranston RE; Schwab C; Elsayed AH; Shi L; Pounds S; Lei S; Baviskar P; Pei D; Cheng C; Bashton M; Sinclair P; Bentley DR; Ross MT; Kingsbury Z; James T; Roberts KG; Devidas M; Fan Y; Chen W; Chang TC; Wu G; Carroll A; Heerema N; Valentine V; Valentine M; Yang W; Yang JJ; Moorman AV; Harrison CJ; Mullighan CG
    Blood; 2023 Aug; 142(8):711-723. PubMed ID: 37216686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
    Ribera JM; Prawitz T; Freitag A; Sharma A; Dobi B; Rizzo F; Sabatelli L; Patos P
    Adv Ther; 2023 Jul; 40(7):3087-3103. PubMed ID: 37208556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Münster 2009 Trial.
    Campbell M; Kiss C; Zimmermann M; Riccheri C; Kowalczyk J; Felice MS; Kuzmanovic M; Kovacs G; Kosmidis H; Gonzalez A; Bilic E; Castillo L; Kolenova A; Jazbec J; Popa A; Konstantinov D; Kappelmayer J; Szczepanski T; Dworzak M; Buldini B; Gaipa G; Marinov N; Rossi J; Nagy A; Gaspar I; Stary J; Schrappe M
    J Clin Oncol; 2023 Jul; 41(19):3499-3511. PubMed ID: 37141547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
    O'Connor D; Demeulemeester J; Conde L; Kirkwood A; Fung K; Papaleonidopoulou F; Bloye G; Farah N; Rahman S; Hancock J; Bateman C; Inglott S; Mee J; Herrero J; Van Loo P; Moorman AV; Vora A; Mansour MR
    J Clin Oncol; 2023 Jul; 41(19):3545-3556. PubMed ID: 37098241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Biomarkers and Molecular Targets in ALL.
    De Sa H; Leonard J
    Curr Hematol Malig Rep; 2024 Feb; 19(1):18-34. PubMed ID: 38048037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
    De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P
    Haematologica; 2024 May; 109(5):1373-1384. PubMed ID: 37941480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
    Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
    Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.
    Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
    Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
    Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.